Abstracts tagged "Amyloidosis"

Abstract Number: 1111 • ACR Convergence 2021
Transient Elastography (fibroscan); As a New Non-invasive Diagnostic Method for Detecting Hepatic Involvement of Amyloidosis
Murat Bektaş¹, Bilger Çavuş², Besim Fazil Agargun³, Volkan Şenkal², Nevzat Koca⁴, Burak Ince⁴, Pelin Özer Karaca⁵, Metban Mestanzade⁶, Melek Büyük⁷, Melike Zehra Buğra⁵, Mine Güllüoğlu⁷, Sevgi Beşışık⁶, Yasemin Yalcinkaya⁸, Bahar Esen⁸, Murat İnanç⁹, Fatih Beşışık² and Ahmet Gül¹⁰, ¹Istanbul Faculty of Medicine, Istanbul, Turkey, ²Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Gastroenterology, İstanbul, Turkey, ³Istanbul Faculty of Medicine, Istanbul University, Department of Internal Medicine, İstanbul, Turkey, ⁴Istanbul Faculty of Medicine, Istanbul University, Division of Rheumatology, İstanbul, Turkey, ⁵Istanbul University, Istanbul Faculty of Medicine, Department of Cardiology, İstanbul, Turkey, ⁶Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Hematology, İstanbul, Turkey, ⁷Istanbul University, Istanbul Faculty of Medicine, Department of Pathology, İstanbul, Turkey, ⁸Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁹Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, ¹⁰Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey
Background/Purpose: Amyloidosis is characterized by accumulation of insoluble fibrils composed of different monomers in extracellular spaces of different organs, and demonstration of deposits by non-invasive…
Abstract Number: 1112 • ACR Convergence 2021
Transient Elastography (Fibroscan) as a Non-Invasive Method for Detecting Amyloid Deposition in Transplanted Kidneys in Patients with AA Amyloidosis
Murat Bektaş¹, Bilger Çavuş², Ahmet Burak Dirim³, Selma Sari⁴, Volkan Şenkal², Nevzat Koca⁴, Burak Ince⁴, Besim Fazil Agargun⁵, Yasemin Yalcinkaya⁶, Bahar Esen⁶, Murat İnanç⁷, Halil Yazıcı³, Fatih Beşışık² and Ahmet Gül⁸, ¹Istanbul Faculty of Medicine, Istanbul, Turkey, ²Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Gastroenterology, İstanbul, Turkey, ³Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Nephrology, İstanbul, Turkey, ⁴Istanbul Faculty of Medicine, Istanbul University, Division of Rheumatology, İstanbul, Turkey, ⁵Istanbul Faculty of Medicine, Istanbul University, Department of Internal Medicine, İstanbul, Turkey, ⁶Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁷Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, ⁸Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey
Background/Purpose: Amyloidosis is characterized by accumulation of insoluble fibrils composed of different monomers in extracellular spaces of different organs, and demonstration of deposits by non-invasive…
Abstract Number: 1214 • 2018 ACR/ARHP Annual Meeting
Comparison of Ultrasound Features of Major Salivary Glands in Sarcoidosis, Amyloidosis, and Sjögren’s Syndrome
Shing Law¹, Praveen Govender², S. Reza Jafarzadeh³, Xianbang Sun⁴, Vaishali Sanchorawala⁵ and Eugene Y. Kissin⁶, ¹Rheumatology, Boston Medical Center, Boston, MA, ²The Pulmonary Center, Sarcoidosis Center, Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁴Boston University, Boston, MA, ⁵Division of Hematology and Oncology, Boston University School of Medicine, Boston, MA, ⁶Rheumatology, Boston University, Boston, MA
Background/Purpose: Salivary gland enlargement occurs in conditions such as Sjögren’s syndrome (SS), sarcoidosis (SAR), and AL amyloidosis (AL). Salivary gland ultrasound (US) has been shown…
Abstract Number: 2975 • 2018 ACR/ARHP Annual Meeting
Anti-Il-1 Therapies in Patients with Familial Mediterranean Fever Related AA-Amyloidosis
Bilgesu Ergezen¹, Serdal Ugurlu², Oguzhan Selvi³, Bugra Han Egeli⁴ and Huri Ozdogan³, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ⁴Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: The most devastating complication of Familial Mediterranean Fever is secondary AA amyloidosis and is still a problem in many cases. Efforts have been paid…
Abstract Number: 943 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of IL-1 Inhibitors in Amyloidosis Associated with Familial Mediterranean Fever Who Underwent Kidney Transplantation
Bahtiyar Toz¹, Yaşar Kerem Çalışkan², Burak Erer¹, Lale Ocal³ and Ahmet Gul¹, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Division of Nephrology, Istanbul School of Medicine, Istanbul University, Istanbul, Turkey, ³Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease characterized by self-limiting febrile attacks associated with serosal or synovial inflammation as well as increased…
Abstract Number: 246 • 2016 ACR/ARHP Annual Meeting
Efficacy of Colchicine and IL-1 Inhibitors in Amyloidosis Associated with Familial Mediterranean Fever: A Retrospective Analysis
Bahtiyar Toz¹, Seher Tecer², Emin Oğuz¹, Murat Erdugan¹, Bahar Artim-Esen¹, Sevil Kamali³, Murat Inanc⁴, Lale Ocal³, Burak Erer¹ and Ahmet Gul¹, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Istanbul faculty of medicine Istanbul University, Istanbul, Turkey, ³Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey
Background/Purpose: Familial Mediterranean fever (FMF), the most common form of hereditary autoinflammatory diseases, is associated with increased risk for secondary (AA) amyloidosis. We herein aimed…
Abstract Number: 260 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Is Effective in the Treatment of AA Amyloidosis Secondary to Familial Mediterranean Fever
Huri Ozdogan¹, Serdal Ugurlu², Aysa Hacioglu², Yasaman Adibnia² and Vedat Hamuryudan², ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Rheumatology, Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: AA amyloidosis is the long-term complication of various chronic inflammatory diseases avoidable by the treatment of the underlying disease but with no established treatment…
Abstract Number: 1581 • 2015 ACR/ARHP Annual Meeting
Cardiac Involvement in Patients with Amyloid a Amyloidosis Due to Rheumatoid Arthritis
Daisuke Kobayashi¹, Satoshi Ito¹, Yoko Wada², Akira Murasawa¹, Ichiei Narita² and Kiyoshi Nakazono¹, ¹Niigata Rheumatic Center, Shibata, Japan, ²Department of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Background/Purpose: Rheumatoid arthritis (RA) is one of the major causes of amyloid A (AA) amyloidosis, the major organs affected being the kidneys and gastrointestinal (GI)…
Abstract Number: 2523 • 2014 ACR/ARHP Annual Meeting
Are Biologic Agents Effective on the Treatment of Secondary Amyloidosis: A Multicenter Report on Turkish Rheumatoid Arthritis and Ankylosing Spondylitis Patients
Omer Nuri Pamuk¹, Umut Kalyoncu², Kenan Aksu³, Salim Donmez⁴, Yavuz Pehlivan⁵, Yonca Cagatay⁶, Ahmet Omma⁷, Orhan Küçükşahin⁸, Gozde Yildirim Cetin⁹, Özün Bayındır¹⁰, Fatih Yildiz¹¹, Ayse Balkarli¹², Levent Kilic¹³, Necati Cakir¹⁴, Bunyamin Kisacik¹⁵, Ahmet Mesut Onat¹⁵, Mustafa Ferhat Özgür¹⁶, Veli Cobankara¹² and Mehmet Sayarlioglu¹⁷, ¹Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ²Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey, ³Rheumatology, Ege University School of Medicine, Izmir, Turkey, ⁴Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey, ⁵Rheumatology, Uludag University, School of Medicine, Bursa, Turkey, ⁶Department of Rheumatology, Bilim University Faculty of Medicine, Istanbul, Turkey, ⁷ROMATOLOJI SERVISI, IST. UNV. TIP FAK. HASTANESI, ISTANBUL, Turkey, ⁸Trakya University Medical Faculty, İstanbul, Turkey, ⁹Ismet Pasa Mah, None, Kahramanmaras, Turkey, ¹⁰Ege University Medical Faculty, Izmir, Turkey, ¹¹Rheumatology, Cukurova University, School of Medicine, Adana, Turkey, ¹²Department of Rheumatology, Pamukkale University School of Medicine, Denizli, Turkey, ¹³Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁴Fatih Sultan Mehmet State Hospital, İstanbul, Turkey, ¹⁵Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ¹⁶Uludag University Medical Faculty, Bursa, Turkey, ¹⁷Rheumatology, KahramanmarasSutçü ImamUniversity School of Medicine, Kahramanmaras, Turkey
Background/Purpose Biologic drugs including anti-TNF agents have been used in the treatment of secondary amyloidosis, however, there is no controlled study concerning the efficacy of…
Abstract Number: 1416 • 2014 ACR/ARHP Annual Meeting
Analysis of Cardiac Involvement in Patients with Amyloid a (AA) Amyloidosis Due to Rheumatoidarthritis
Daisuke Kobayashi¹, Satoshi Ito¹, Satoru Kodama¹, Akira Murasawa¹, Ichiei Narita² and Kiyoshi Nakazono¹, ¹Niigata Rheumatic Center, Shibata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Background/Purpose Rheumatoid arthritis (RA) is one of the major causes of amyloid A (AA) amyloidosis. The major organs affected are the kidneys and gastrointestinal (GI)…
Abstract Number: 1233 • 2014 ACR/ARHP Annual Meeting
Tocilizumab (TCZ) in the Treatment of AA Amyloidosis in Patients with Familial Mediterranean Fever
Huri Ozdogan, Serdal Ugurlu, Aysa Hacioglu, Yasaman Adibnia and Vedat Hamuryudan, Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: AA amyloidosis is the major long-term complication of various chronic inflammatory diseases like rheumatoid arthritis, ankylosing spondylitis, FMF and other autoinflammatory syndromes. Treatment of…
Abstract Number: 568 • 2014 ACR/ARHP Annual Meeting
Secondary Amyloidosis Complicating Spondyloarthritis: Still Present after All These Years
Samantha Rodriguez-Muguruza¹, Melania Martínez-Morillo¹, Susana Holgado¹, Maria Lourdes Mateo¹, Juana Sanint¹, Anne Riveros-Frutos², Jeronima Cañellas¹, Xavier Tena¹ and Alejandro Olivé Marqués¹, ¹Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ²Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Secondary amyloidosis (AA) is a disorder caused by deposition of insoluble amyloid A fibrils in different tissues and organs. It is a rare and…
Abstract Number: 2387 • 2013 ACR/ARHP Annual Meeting
Change of serum Amyloid a predict The Effect Of Biological Treatment In Rheumatoid Arthritis Patient
Chisa Okura¹, Yukio Yonemoto², Koichi Okamura¹, Tetsuya Kaneko³, Tsutomu Kobayashi¹ and Kenji Takagishi¹, ¹Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, ²Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan, ³Department of Orthopaedic Surgery, Inoue Hospital, Takasaki, Gunma, Japan
Background/Purpose: The C-reactive protein (CRP) level and the erythrocyte sedimentation rate (ESR) are common markers of inflammation in patients with rheumatoid arthritis (RA). The serum…
Abstract Number: 2389 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Survives Introducing The Hemadialysis Longer Than Oral Medicine In AA Amyloidosis Patients With Rheumatoid Arthritis Of Renal Insufficiency
Osamu Saiki¹, Hiroshi Uda¹, Ayumi Matsumoto², Aya Mizumoto³, Tamaki Harada³ and Toshirou Takama³, ¹Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan, ²Higashiosaka City General Hospital, Higashiosaka, Japan, ³Nephrology, Higashiosaka City General Hospital, Higashiosaka, Japan
Background/Purpose: In AA amyloidosis patients with RA taking oral medicines such as methotrexate and prednisolone, it is generally accepted that the renal function deteriorates gradually…
Abstract Number: 1659 • 2013 ACR/ARHP Annual Meeting
Systematic Review Of Amyloid Beta-Related Angiitis: A Treatable Cause Of Vasculitis Affecting Central Nervous System
Abhijeet Danve¹ and Atul A. Deodhar², ¹Rheumatology, Oregon Health and Science University, Portland, OR, ²Oregon Health and Science University, Portland, OR
Background/Purpose: Amyloid β-related angiitis (ABRA) is a rare type of Central Nervous System Vasculitis (CNSV), which complicates Cerebral Amyloid Angiopathy (CAA). Data about clinical features,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].